<div id="readability-page-1"><p>Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.08, FiscalAI reports. The company had revenue of $621.94 million for the quarter, compared to analysts' expectations of $578.57 million. Aveanna Healthcare had a net margin of 3.29% and a negative return on equity of 103.46%.  Aveanna Healthcare updated its FY 2025 guidance to  EPS.</p><div><p><span></span><span>Get <strong>Aveanna Healthcare</strong> alerts:</span></p></div><h2>Aveanna Healthcare Price Performance</h2><p>AVAH traded up $0.12 during trading on Friday, reaching $8.75. The company had a trading volume of 1,381,278 shares, compared to its average volume of 1,771,923. The company has a market cap of $1.83 billion, a P/E ratio of 24.31 and a beta of 2.04. Aveanna Healthcare has a 12 month low of $3.67 and a 12 month high of $10.32. The business's fifty day moving average price is $8.86 and its 200 day moving average price is $6.48. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities analysts recently weighed in on the company. UBS Group increased their price target on Aveanna Healthcare from $9.00 to $9.50 and gave the company a &#34;neutral&#34; rating in a research report on Friday. Raymond James Financial raised Aveanna Healthcare from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $9.00 price target for the company in a research note on Monday, August 11th. Weiss Ratings  reissued a &#34;hold (c)&#34; rating on shares of Aveanna Healthcare in a research report on Wednesday, October 8th. Barclays upgraded Aveanna Healthcare from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and boosted their target price for the stock from $5.50 to $9.50 in a report on Tuesday, August 19th. Finally, Royal Bank Of Canada increased their price target on Aveanna Healthcare from $8.00 to $10.00 and gave the company a &#34;sector perform&#34; rating in a report on Friday, October 24th. Three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and a consensus price target of $10.07.</p><p><b>Read Our Latest Analysis on Aveanna Healthcare</b></p><h2>Insider Activity at Aveanna Healthcare</h2><p>In related news, major shareholder Robert M. Williams, Jr. sold 1,500,000 shares of the company's stock in a transaction on Friday, October 24th. The shares were sold at an average price of $9.00, for a total value of $13,500,000.00. Following the completion of the transaction, the insider directly owned 362,746 shares of the company's stock, valued at approximately $3,264,714. This represents a 80.53% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, major shareholder Paul R. Vigano sold 1,500,000 shares of the stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $9.00, for a total value of $13,500,000.00. Following the transaction, the insider owned 362,746 shares of the company's stock, valued at approximately $3,264,714. This trade represents a 80.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 32,597,968 shares of company stock valued at $293,381,712. 7.80% of the stock is owned by corporate insiders. </p><h2>Institutional Investors Weigh In On Aveanna Healthcare</h2><p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVAH. Vanguard Group Inc. boosted its stake in shares of  Aveanna Healthcare by 34.7% during the 3rd quarter. Vanguard Group Inc. now owns 4,041,659 shares of the company's stock worth $35,850,000 after buying an additional 1,041,324 shares during the last quarter.  Squarepoint Ops LLC increased its position in shares of  Aveanna Healthcare by 207.0% during the 2nd quarter. Squarepoint Ops LLC now owns 479,977 shares of the company's stock worth $2,510,000 after purchasing an additional 323,656 shares during the last quarter.  Qube Research &amp; Technologies Ltd raised its stake in shares of  Aveanna Healthcare by 92.4% during the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 437,838 shares of the company's stock worth $2,290,000 after purchasing an additional 210,288 shares in the last quarter.  Lazard Asset Management LLC acquired a new stake in shares of  Aveanna Healthcare in the 2nd quarter valued at approximately $791,000.  Finally, Ameriprise Financial Inc. grew its stake in shares of  Aveanna Healthcare by 168.0% in the second quarter. Ameriprise Financial Inc. now owns 145,982 shares of the company's stock valued at $763,000 after buying an additional 91,508 shares in the last quarter. 87.96% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Aveanna Healthcare Company Profile</h2> (Get Free Report)<p>Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Aveanna Healthcare</li><li>Business Services Stocks Investing</li><li>e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts</li><li>About the Markup Calculator</li><li>T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?</li><li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li><li>Qualcomm Earnings Surprise Wall Street—Here’s What Q4 Could Deliver</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZBSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZBSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Aveanna Healthcare Right Now?</h2><p>Before you consider Aveanna Healthcare, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aveanna Healthcare wasn't on the list.</p><p>While Aveanna Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AVAH

<p>Aveanna Healthcare (NASDAQ:AVAH) reported earnings of $0.15 EPS for the quarter, exceeding estimates of $0.07. Revenue reached $621.94 million, surpassing expectations of $578.57 million. The company has a negative return on equity of 103.46% and a net margin of 3.29%. Aveanna updated its FY 2025 guidance. Analysts have mixed ratings, with price targets ranging from $9.00 to $10.00. Recent insider sales totaled 32.6 million shares, and institutional investors have increased their stakes in the company.</p>

Aveanna Healthcare (NASDAQ:AVAH) Issues Earnings Results